Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Sep 15, 2022 5:29pm

115 Views

Post# 34965546

AGN's DMT study for treating stroke

Algernon Pharmaceuticals Inc. (AGN.c AGNPF) received approval to conduct a clinical study on treating stroke with DMT.

The first part of AGN's study will try to identify a safe non-psychedelic dose of DMT while the second part will test the effects of repeated administrations of the non-psychedelic dose.

In a prior study, AGN found that DMT increased the growth of cortical neurons by up to 40% compared to control in its own pre-clinical study.

Hopefully, we will see the success of that study replicated for this latest study. The company plans to dose the first subject of the study this fall.

https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/163/algernon-pharmaceuticals-receives-approval-for

AGN @ $5.06

MC $11.931M

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?